Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP7 | P09237 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875350 | 0.87 | S1PR1 (0.57) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL13875332 | 0.81 | S1PR1 (0.60) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL13875345 | 0.75 | S1PR1 (0.72) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL13875330 | 0.71 | S1PR1 (1.00) | S1PR1KMT2ACA2CYP2D6CYP2C19 | |
| SCHEMBL13875329 | 0.71 | S1PR1 (0.77) | S1PR1KMT2ACA2CYP2D6CYP2C19 | |
| SCHEMBL4170249 | 0.70 | S1PR1 (0.53) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL4164417 | 0.66 | S1PR1 (0.60) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL4164065 | 0.66 | S1PR1 (0.60) | S1PR1KMT2AMMP2MMP1MMP3 | |
| SCHEMBL7909439 | 0.65 | CA2 (0.61) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL4165318 | 0.65 | S1PR1 (0.59) | S1PR1KMT2ACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ADGRE5, ADGRF1, SELPLG | S1PR1 677/4885KMT2A 4098/4885MMP2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.